WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsOmnicell Inc (OMCL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 144% more annual revenue ($2.89B vs $1.18B). OMCL leads profitability with a 0.2% profit margin vs -7.3%. OMCL earns a higher WallStSmart Score of 39/100 (F).

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 5.0Quality: 5.0

OMCL

Hold

39

out of 100

Grade: F

Growth: 2.7Profit: 4.0Value: 2.0Quality: 6.3
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

OMCLSignificantly Overvalued (-13907.4%)

Margin of Safety

-13907.4%

Fair Value

$0.27

Current Price

$34.94

$34.67 premium

UndervaluedFair: $0.27Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED0 strengths · Avg: 0/10

No standout strengths identified

OMCL2 strengths · Avg: 9.5/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

OMCL4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Market CapQuality
$1.57B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.2%3/10

ROE of 0.2% — below average capital efficiency

Profit MarginProfitability
0.2%3/10

0.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : OMCL

The strongest argument for OMCL centers on Price/Book, Debt/Equity.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Bear Case : OMCL

The primary concerns for OMCL are Revenue Growth, Market Cap, Return on Equity. A P/E of 861.5x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

MMED profiles as a turnaround stock while OMCL is a value play — different risk/reward profiles.

MMED is growing revenue faster at 13.1% — sustainability is the question.

OMCL generates stronger free cash flow (20M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

OMCL scores higher overall (39/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Omnicell Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.

Want to dig deeper into these stocks?